Fig 2.
Overall survival and progression-free survival probability based on combined ADC and rCBV measurements. A and C, Patient outcome as a function of combined stratification by using ADCmin and rCBVmean. Patients stratified into the low-low group (ADCmin < 384, rCBVmean < 1.43; dashed line), high-high group (ADCmin ≥ 384, rCBVmean ≥ 1.43; solid line), and mixed (low ADCmin and high rCBVmean or high ADCmin and low rCBVmean; dotted line). Kaplan-Meier analysis (A) of OS shows decreased median survival for the low-low group of 7.9 months and a median survival of 36.0 months for the mixed group (P < .01, logrank test). Kaplan-Meier analysis (C) of PFS shows a median progression for the low-low group of 2.5 months and a median progression of 36 months for the mixed group (P < .01, logrank test). C and D, Patient outcome as a function of combined stratification by using ADCmin and rCBVmin: patients stratified into the low-low group (ADCmin < 384, rCBVmin < 0.56; dashed line), high-high group (ADCmin ≥ 384, rCBVmin ≥ 0.56; solid line), and mixed (low ADCmin and high rCBVmin or high ADCmin and low rCBVmin; dotted line). Kaplan-Meier analysis shows statistically significant differences between groups in overall survival and progression (P < .01, logrank test for OS; P < .01, logrank test for PFS).